Latest topics
» UFO News ~ Driver pulls to the roadside to film a HUGE object soaring over the Ocean! plus MORE
Today at 10:29 am by PurpleSkyz

» Liz Crokin Update - Part 1&2
Today at 10:24 am by PurpleSkyz

» EMERGENCY REPORT: Trump Planning Mass Arrests, Military Tribunals for Deep State Traitors
Today at 1:30 am by PurpleSkyz

» Are all pharmaceuticals designed for population control?
Today at 1:29 am by PurpleSkyz

» How Cannabis Fights Depression
Today at 1:22 am by PurpleSkyz

» NIBIRU News ~ Crazy sky TWO SUNS APPEAR Clear in sunrise Rome New York plus MORE
Today at 12:49 am by PurpleSkyz

» Ranmasu Uyana - Stargate of Gods Found? Ancient Aliens in Sri Lanka
Today at 12:41 am by PurpleSkyz

» SPORTS FROM THE FUTURE~ INVENTED BY TS CALADAN
Yesterday at 10:34 pm by PurpleSkyz

» James Gilliland - As You Wish BBS Talk Radio - Saturday 9/22/2018 (Audio Only) With Maria Wheatley.
Yesterday at 6:39 pm by PurpleSkyz

» Steven Greer - Contact and the Cosmos
Yesterday at 6:38 pm by PurpleSkyz

» #Q ANON: Did [[RR]] Resign? plus MORE
Yesterday at 6:30 pm by PurpleSkyz

» Julian Assange's Last Words "Intelligent Evil Dust, it's Everywhere in Everything" Then Cut Off Air
Yesterday at 6:26 pm by PurpleSkyz

» FEMA Employee Tells All
Yesterday at 6:22 pm by PurpleSkyz

» MORE ON THE SUNSPOT OBSERVATORY CLOSURE, PART ONE
Yesterday at 3:38 pm by ~Ann~

» Carrying Stones & Digging Holes Radio Show September 22, 2018
Yesterday at 12:21 pm by Consciousness Of Economic

» How Our Energy/Power Systems Work
Yesterday at 12:16 pm by Consciousness Of Economic

» Bill Gates vs. freedom by Jon Rappoport
Yesterday at 10:32 am by PurpleSkyz

» Exploring Trichomes, the Key to the Power of Cannabis
Yesterday at 10:29 am by PurpleSkyz

» This Ancient Hindu Temple Was Carved Out Of A Single Rock, And No One Knows How
Yesterday at 10:21 am by PurpleSkyz

» “The Truth About Pepe the Frog and the Cult of Kek”
Yesterday at 10:07 am by PurpleSkyz

» The Rover Curiosity sent an image where you clearly see a Shelter
Yesterday at 10:00 am by PurpleSkyz

» UFO News ~ Multiple RED LIT UFOS Caught on film OVER CALIFORNIA plus MORE
Yesterday at 9:49 am by PurpleSkyz

CLICK THE SUBSCRIBE BUTTON BELOW TO RECEIVE OUR DAILY NEWSLETTER

A 2ND EMAIL COMPLETES THE ACTIVATION PROCESS




CLICK THE PURPLE BUTTON TO VIEW OUR LATEST POSTS



 photo d4ada2c6-6aaf-4501-aed0-310211c0d995_zpsuek7kljv.jpg
ONLY NATURES MAGIC
Featuring Homemade Herbal Salves Made From the Ozarks
https://onlynaturesmagic.com



CONTACT PURPLESKYZ
FOR DETAILS


Oily Rocks Essentials
Oily Rocks
Boutique Essential Oil
Roller Bottles
https://oily-rocks.com



CONTACT PURPLESKYZ
FOR DETAILS


Key Word Topics:
11:11, Aliens, Angels, Antarctica, Ascension, Assange, Astral Projection, Auras, Bankers, Bitcoin, Blood Type, Booms, BRICS, Cabal, Cannabis, CBD, CERN, Chemtrails, CME's, Consciousness, Conspiracy Theories, Crypto Currency, Crystals, Dinar, Dinar Scam, Disclosure, Earthquakes, EMF, Empaths, Environment, ESP, ET's, False Flags, Federal Reserve, Flooding, Fluoride, Fracking, Fraud, Fukushima,GMO's, Herbs, History, Holistic, Illuminati, IMF, ISS, Ley Lines, Lucid Dreaming, Mandela Effect, Medical, Meteor, MKUltra, Monsanto, Morgellons, NASA, Nature, Nesara, Nibiru, Night Sky, NDE's, Numerology, NWO, OD's, Organic, Paranormal, Pizzagate, Planet X, Predictive Programming, Protests, Psychic, Q Anon, Radiation, Reincarnation, Remote Viewing, RH Negative Blood, RV, Sacred Geometry, Scams, Science, SETI, Shadow People, Shift, Sink Holes, Smart Meters, Space Force, Space X, Spirit Animals, Sun Simulator, Synchronicity, Technology, TDA, THC, UFO, Vatican, Vaccines, Volcano, WIFI, Wikileaks

You are not connected. Please login or register

Out Of Mind » THE INSANITY OF REALITY » VACCINE TRUTHS: MEDICAL INDUSTRY LIES » The Pharma Drug That Is Bankrupting America

The Pharma Drug That Is Bankrupting America

Go down  Message [Page 1 of 1]

1 The Pharma Drug That Is Bankrupting America on Wed Feb 18, 2015 1:02 pm

PurpleSkyz

avatar
Admin
The Pharma Drug That Is Bankrupting America
How can Gilead Sciences charge $84,000 for a drug that costs less than $300 to produce?
By Jeffrey Sachs / The Huffington Post
February 17, 2015



Print
68 COMMENTS
America is the land of breakthrough science -- and health care scams. The two seem to go hand in hand in the case of the new hepatitis C virus (HCV) cure named sofosbuvir, sold under the brand name Sovaldi by the drug company Gilead Sciences. There is no question that Solvadi is a godsend -- a lifesaver for millions of Americans, and perhaps someday for hundreds of millions of people around the world infected by Hepatitis C. Yet Sovaldi is also the poster child of a U.S. health care system that is being bankrupted by greed, lobbying and indefensible policies on drug pricing.
The basic facts are these. In December 2013, the Food and Drug Administration approved Sovaldi, and another formulation, Harvoni, which is sofosbuvir used in combination with another drug. Gilead set the price for a 12-week treatment course of Sovaldi at $84,000, amounting to $1,000 per pill. Gilead set the price of Harvoni at $94,000.
According to researchers at Liverpool University, the actual production costs of Sovaldi for the 12-week course is in the range $68-$136. Indeed, generic sofosbuvir is currently being marketed in India at $300 per treatment course, after India refused to grant Gilead a patent for the Indian market. In other words, the U.S. price-cost markup is roughly 1,000-to-1!
How can Gilead Sciences charge $84,000 for a drug that costs less than $300 to produce? First, Gilead's patent on sofosbuvir runs until 2028, giving it a monopoly in the U.S. market. Second, a range of Federal and state government programs will cover the $84,000 for a sizeable number of patients. For those not covered by government programs, some will be covered by private insurance, a few will pay out of pocket, and still others will likely die because they lack coverage and can't afford the treatment.
In the first year of marketing, Sovaldi and Harvoni are already blockbusters, reaping a remarkable $12.4 billion of market sales in 2014, more in just one year than the $11.2 billion price that Gilead paid in January 2012 to buy sofosbuvir from a biotech start-up named Pharmasett.
The standard defense by the drug companies of these astronomical prices is that drug discovery is costly and their high profits reimburse the R&D costs. Here is where the story of Sovaldi gets even more interesting. The total private-sector outlays on R&D were perhaps $300 million, and almost surely under $500 million, meaning that the decade-long R&D outlays were likely recouped in a few weeks of drug sales.
Here is the background. Sofosbuvir was developed under the leadership of Prof. Raymond Schinazi, a brilliant professor of biochemistry at Emory University. The U.S. Government heavily funded Prof. Schinazi's research, with major grants from the National Institutes of Health (NIH) and support from the Veterans Administration. Like many academic researchers, Schinazi has frequently parlayed his government grants into private companies to market his discoveries. He set up Pharmasset Inc. as a Delaware corporation in 2004 as his business to develop sofosbuvir and hold the patents on the new prospective drug.
Pharmasset raised around $45 million in a 2007 IPO and used those funds and others to supplement the R&D. According to the company's SEC filings, the total Pharmasset R&D on sofosbuvir up through 2011 totaled around $62.4 million. In January 2012, with an eye on sofosbuvir, Gilead paid $11.2 billion to purchase Pharmasett. Schinazi pocketed an estimated $440 million for his shares in Pharmasett.
By the fall of 2011, sofosbuvir was ready for Phase 2 clinical trials, which were carried out between October 2011 and April 2012 by the NIH, which published the results in the Journal of the American Medical Association in 2013. Phase 3 trials were then carried out in mid-2013 and were paid by Gilead, at a cost of perhaps $50-$100 million for a two-month trial that covered around one thousand patients. (Gilead has not disclosed the exact costs of the Phase 3 trials).
We can therefore estimate that private investors spent perhaps $300 million in R&D outlays for sofosbuvir over the course of a decade, and perhaps well below that sum. Those R&D outlays were likely recouped in a few weeks of sales in 2014.
With a rational U.S. drug pricing system, private investors would expect to earn a reasonable multiple of their R&D for a highly successful drug, perhaps even 5 to 10 times the R&D outlays, in order to reflect the long time horizons and high uncertainties surrounding drug development. Yet at a treatment course of $84,000, the multiple for Sovaldi looks to be around 40 times or more.
With a rational drug pricing system, Gilead might have paid $1 billion rather than $11.2 billion for the drug, and Prof. Schinazi might have pocketed $40 million rather than $440 million. Sovaldi would most likely still have been developed and brought to market on the same timeline, but with taxpayers spared of perhaps $10 billion a year in outlays.
Gilead has worked the political system to protect its windfall by ramping up its lobbying activities. That soared to $2.2 million in 2013, the year of FDA approval, and $2.9 million in 2014, the first year of sales. The lobbying helped to smooth the way to the massive uptake of the drug and the substantial financing by the U.S. Government of Gilead's inflated prices.
Sovaldi therefore represents the best and the worst of the U.S. health system. It represents the best of U.S. produced science, and the government's support for it. Sofosbuvir is a remarkable, life-saving medicine at the cutting edge of science.
Yet Sovaldi also shows how publicly financed science easily turns into arbitrarily large private profits paid for by taxpayers. The challenge facing the U.S. is to adopt a rational drug pricing system that continues to spur excellent scientific breakthroughs while keeping greed in check. Big Pharma and the U.S. public are on a collision course when they should be partners for the advancement of health.
Jeffrey D. Sachs is a world-renowned professor of economics, leader in sustainable development, senior U.N. advisor, bestselling author, and syndicated columnist whose monthly newspaper columns appear in more than 100 countries. He has twice been named among Time Magazine’s 100 most influential world leaders. Professor Sachs serves as the Director of The Earth Institute, Quetelet Professor of Sustainable Development, and Professor of Health Policy and Management at Columbia University. Sachs has authored three New York Times bestsellers in the past seven years, including "The End of Poverty." A native of Detroit, Michigan, Sachs received his B.A., M.A., and Ph.D. degrees at Harvard.


Thanks to: http://www.alternet.org



  

Back to top  Message [Page 1 of 1]

Permissions in this forum:
You cannot reply to topics in this forum